T01

About Treamid Therapeutics

Treamid Therapeutics is a private, preclinical-stage biotech developing small molecule drugs for fibrotic and inflammatory conditions. Its lead asset, T03, has completed a Phase 1a study and is positioned for idiopathic pulmonary fibrosis (IPF), with additional exploratory programs in liver and renal fibrosis. The company operates with a lean model, leveraging collaborations with academic institutions and CROs while maintaining an in-house research lab to drive its discovery efforts forward.

Therapeutic Areas